Tom 19, Nr 3 (2023)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2023-10-04
Wyświetlenia strony
213
Wyświetlenia/pobrania artykułu
98
Przegląd piśmiennictwa
1
DOI: 10.5603/ppn.97416
Pol. Przegl. Neurol 2023;19(3):253-255.
Streszczenie
Brak
Referencje
- Payne T, Appleby M, Buckley E, et al. A double-blind, randomized, placebo-controlled trial of ursodeoxycholic acid (UDCA) in Parkinson's disease. Mov Disord. 2023; 38(8): 1493–1502.
- Hannaway N, Zarkali A, Leyland LA, et al. Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2023; 94(9): 742–750.
- Flores-Torres MH, Christine CW, Bjornevik K, et al. Long-term intake of folate, vitamin B6, and vitamin B12 and the incidence of Parkinson's disease in a sample of U.S. Women and Men. Mov Disord. 2023; 38(5): 866–879.
- Cuoco S, Ponticorvo S, Abate F, et al. Frequency and imaging correlates of neuropsychiatric symptoms in progressive supranuclear palsy. J Neural Transm (Vienna). 2023; 130(10): 1259–1267.
- Furr Stimming E, Claassen DO, Kayson E, et al. Huntington Study Group KINECT-HD Collaborators. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023; 22(6): 494–504.
- Shi Z, Zhang J, Wang P, et al. Serum lipid levels are associated with orthostatic hypotension in multiple system atrophy patients. Parkinsonism Relat Disord. 2023; 114: 105803.
- Altmann CF, Koschel J, Jost WH. Predictors of falls in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a retrospective study. Neurol Neurochir Pol. 2023; 57(3): 297–304.
